0:00
Hi.
My name is Ben Seon.
Today I'm going to talk
about human tumor antigens
as the therapeutic target of cancer.
0:13
Tumor cells express many
different type of antigens.
And I listed some of these
antigens that potentially
can be used for targeting purposes.
First, products of oncogenes and
the tumor suppressor gene products
and cancer-Testis antigen,
oncofetal antigen, differentiation
antigen, and angiogensesis
associated antigen,
and immune checkpoint molecule.
Traditionally, immune checkpoint
molecule is not included
in the tumor antigens. But due to
recent successes by James Allison
and his group, and also others,
for targeting this molecule,
I include it here.
However, I'm not going
to talk about this one
because other speakers
will discuss this topic
in this series of lectures.
1:23
Druker and his associates
targeted and treated, CML,
chronic myeloid leukemia
patients, who express BCR-ABL
tyrosine kinase inhibitors.
This is a fusion protein
using a specific inhibitor, Gleevec.
Now the result is striking.
In dose escalation
studies, at highest dose,
there is a 300 to 1,000
milligram per day.
53 out of 54 patient
responded completely.
A complete response of 98%.
So this is an amazing result.
